Article: Collaboration for Aspirin Resistance Testing Announced by Corgenix Medical Corporation, Creative Clinical Concepts, Inc. and McMaster University.

Technology Used to Determine a Patient's Response to Aspirin Therapy Taken to Prevent Heart Attacks

Corgenix Medical Corporation ("Corgenix") (BULLETIN BOARD: CONX) and AspirinWorks, a division of Creative Clinical Concepts, Inc. ("CCC"), both headquartered in Denver, Colorado, today announced that together they have entered into a license agreement with McMaster University ("McMaster"), Hamilton, Ontario, providing Corgenix and CCC exclusive rights to the propriety technology owned by McMaster for the development, manufacturing and marketing of innovative diagnostic tests specific to the pathway by which aspirin acts on platelets. This technology has ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!